Summit Therapeutics Inc.

Pharmaceutical Preparations·MIAMI, FL·FY end 12/31·CIK 1599298

CEO Pay Ratio

489:1

Robert W. Duggan

CEO Total Comp

$172.4K

Robert W. Duggan

Median Employee

$321,400

Revenue

—

FY 2025

Net Income

-$1.1B

FY 2025

Free Cash Flow

-$323.6M

FY 2025

Net Margin

—

Insider Net (180d)

0 buys / 0 sales

CEO Pay Accountability

CEO comp as % of net income

-0.02%

For every $1,000 of profit, $-0.16 flows to the CEO.

CEO comp as % of buybacks

—

No buyback data for the most recent fiscal year.

5-year history · USD

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	Trend
Revenue	—	$0	$0	$705.0K	$1.8M
Gross Profit	—	—	—	—	—	—
Operating Income	—	-$226.0M	-$609.6M	-$72.1M	-$86.2M
Net Income	-$1.1B	-$221.3M	-$614.9M	-$78.8M	-$88.6M
Operating CF	-$322.9M	-$142.1M	-$76.8M	-$41.6M	-$72.6M
Capex	$657.0K	$139.0K	$128.0K	$624.0K	$306.0K
Free Cash Flow	-$323.6M	-$142.2M	-$76.9M	-$42.2M	-$72.9M
Buybacks	—	—	—	—	—	—
Dividends	—	—	—	—	—	—

Gross Margin	—	—	—	—	—	—
Operating Margin	—	—	—	-10225.4%	-4764.3%
Net Margin	—	—	—	-11174.8%	-4897.8%
FCF Margin	—	—	—	-5986.7%	-4029.5%
R&D / Revenue	—	—	—	7375.7%	4718.2%
Effective Tax	0.0%	—	—	—	0.0%
Debt / Equity	—	—	—	—	—	—
Buybacks / FCF	—	—	—	—	—	—

FY 2025

Executive	Salary	Stock	Options	Bonus / Inc.	Other	Total
Robert W. DugganCo-Chief Executive Officer and Chairman	—	—	—	—	—	$172.4K
Mahkam ZanganehCo-Chief Executive Officer, President and Director	$616.5K	—	—	$388.4K	$245.0M	$21.0K
Manmeet SoniChief Operating Officer, Chief Financial Officer and Director	$616.5K	—	—	$388.4K	$248.1M	$21.0K